GlassScriptPhysician profile
Julius S Vonclef
NPI 1740226646
$3,566.71
in general payments reported to CMS, 2019-2025
37 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $519 · 2021: $691 · 2022: $452 · 2023: $505 · 2024: $636 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,421.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $321.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $314.84 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $289.96 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.90 | 2019-2025 | Jardiance, Ofev |
| Pfizer INC. | $256.69 | 2019-2024 | |
| Abbvie INC. | $229.42 | 2021-2024 | Ubrelvy, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $223.53 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $166.68 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $143.31 | 2024-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $139.69 | 2020-2024 | Jardiance, Zepbound, Emgality |
| Heartflow, INC. | $131.95 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $113.58 | 2023-2025 | Rexulti |
| Allergan, INC. | $107.75 | 2019-2020 | |
| Abbott Laboratories | $89.47 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Xeris Pharmaceuticals, INC. | $79.24 | 2021-2023 | Gvoke Hypopen |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Vonclef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.